Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
07 Juin 2024 - 7:00AM
Ipsen and Marengo Therapeutics announce second strategic
partnership to advance precision T cell engagers from Marengo’s
Tri-STAR platform
- Using
Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their
ongoing oncology research to include up to two additional assets in
new early development collaboration
- Research
will focus on using Marengo’s TriSTAR platform to reinvigorate and
mobilize selective Vβ T cells to boost anti-tumor activity in
patients with traditionally difficult-to-treat ‘cold’
tumors
PARIS, FRANCE, and CAMBRIDGE, MA, U.S.,
07 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and
Marengo Therapeutics Inc, a clinical-stage biotech company,
announced today the expansion of their ongoing oncology research
partnership, to include TriSTAR, Marengo’s next-generation,
precision T cell engager (TCE) technology. Traditional TCEs
targeting ‘cold’ tumors have limited efficacy due to poor T cell
quality and exhaustion. Marengo’s proprietary first-in-class
TriSTAR TCEs have the potential to overcome these limitations,
redirecting a new and expanded pool of highly activated memory Vβ T
cells to the tumor. The teams will focus on exploring potential in
‘cold’ tumors which typically fail to trigger a strong immune
response when treated with TCEs.
“We take a science-first approach to expanding
our pipeline and are delighted to continue our strong work with the
teams at Marengo, who share our passion and drive to accelerate
cancer innovations,” said David Jenkins, SVP, Research and External
Innovation at Ipsen. “Through Marengo’s next-generation TriSTAR
platform we have the potential to unlock the power of the immune
system, activating a wider pool of T cells to eradicate tumors that
traditionally have a weak response to T-cell immunotherapies.”
“We are excited to build on our existing
research collaboration with Ipsen, which has already successfully
delivered the first development candidate earlier this year,” said
Zhen Su, CEO of Marengo Therapeutics. “This new collaboration with
Ipsen builds on our clinically validated TCR Vβ platform and our
internal work with new TriSTAR T cell engagers that suggest
best-in-class potential and the ultimate precision IO goal of
delivering the right T cells to the right tumor. The TriSTAR
platform significantly expands our portfolio to target
difficult-to-treat ‘cold’ tumors, and we are thrilled to partner
with the Ipsen oncology team to realize this ambition
together.”
Under the terms of the agreement, Ipsen will
assume responsibility for all activities following development
candidate nomination. Marengo will receive an upfront payment and
potential payments up to a total of $1.2 billion if all milestones
are met in addition to tiered sales royalty payments.
ENDS
About Ipsen
We are a global biopharmaceutical company with a
focus on bringing transformative medicines to patients in three
therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
About Marengo
Marengo Therapeutics, Inc, a clinical-stage
biotech company, develops novel TCR-targeting antibodies that
selectively modulate common and disease-specific T cell subsets of
the germline TCR repertoire to provide lifelong protection against
cancer and other diseases. With a passionate team of dedicated
scientists experienced in immunology and oncology, Marengo’s
proprietary Selective T Cell Activation Repertoire (STAR) platform
leverages an extensive biological understanding of T cell function
and receptor signaling to create a world in which everyone’s immune
system can defeat cancer. To learn more, visit marengotx.com.
About TriSTAR Platform
Marengo’s TriSTAR platform is a multi-specific
antibody-fusion platform derived from Marengo’s proprietary library
of antibodies targeting germline-encoded variable Vβ regions of the
TCR, fused to a T cell co-stimulatory moiety and a tumor-associated
antigen binder. By expanding and redirecting a new pool of highly
activated memory Vβ T cells, TriSTAR TCEs have the potential to
overcome the effects of poor T cell quality and T cell exhaustion
that may limit the activity of traditional TCEs.
Email:
corporate.communications@ipsen.com
Ipsen contacts
Investors
Craig Marks | + 44 7584 349
193
Nicolas Bogler | +33 (0) 6 52
19 98 92
Media
Amy Wolf | +41 7 95 76 07
23
Jess Smith | + 44 7557 267
634
Marengo contacts
Investors
Svetlana Makhni |
smakhni@marengotx.com
Media
Peg Rusconi |
peg.rusconi@vergescientific.com
Disclaimers and/or Forward-Looking
StatementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Ipsen PR_Marengo_07062024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024